

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

These amendments introduce no new matter and support for the amendment is replete throughout the specification and claims as originally filed. These amendments are made without prejudice and are not to be construed as abandonment of the previously claimed subject matter, or agreement with any objection or rejection of record.

Listing of Claims:

1. (Previously presented) A method of making an antibody that specifically binds to cytochrome P450 CYP1B1, the method comprising raising the antibody using a peptide consisting of an amino acid sequence VNQWSVNHDPVKWPN (SEQ ID NO: 1) or PExFDPARFLDKDGy, where x is D or N and y is L or F (SEQ ID NOs 2 to 5), or an antigenic fragment thereof.

2. (Original) The method of claim 1, wherein the peptide consists of 3 to 10 amino acids.

3. (Previously Presented) The method of claim 1, wherein the peptide consists of 3 to 6 amino acids.

4. (Previously Presented) The method of claim 1, wherein the peptide is conjugated to an immunogenic carrier.

5. (Original) The method of any one of the preceding claims, wherein the antibody is a monoclonal antibody.

6. (Original) The method of claim 5, wherein the monoclonal antibody is as obtainable by a method which comprises:

- (a) immunising an animal with the peptide conjugated to an immunogenic carrier;
- (b) sacrificing the animal and fusing spleen cells obtained from the animal with myeloma cells to produce one or more hybridomas ; and,
- (c) screening the hybridomas for antibodies capable of binding the peptide.

7. (Original) A method of producing an antibody having obtained a hybridoma by the method of claim **6**, the method comprising culturing a hybridoma found in step (c) and isolating the antibody thus produced.

8. (Original) The method of claim **7**, further comprising conjugating the antibody to an effector.

9. (Original) The method of claim **8**, wherein the effector is a label, a toxin, a drug or prodrug, an enzyme or a transport molecule.

10. (Previously presented) An isolated monoclonal antibody which is capable of specifically binding to cytochrome P450 CYP1B1, wherein the monoclonal antibody recognises an epitope in the cytochrome P450 CYP1B1 protein included within the amino acid sequence VNQWSVNHD^xPVKW^yPN (SEQ ID NO: 1) or PExFD^xPARFLDKD^yGy, where x is D or N and y is L or F (SEQ ID NOs: 2 to 5).

11. (Original) The antibody of claim **10**, wherein the antibody recognises an epitope of between 3 and 10 amino acids from the amino acid sequences.

12. (Original) The antibody of claim **10**, wherein the antibody recognises an epitope of between 3 and 6 amino acids from the amino acid sequences.

13. (Cancelled) The antibody of claim **10**, wherein the antibody is a monoclonal antibody.

14. (Previously Presented) The antibody of claim **10** which is humanised.

15. (Currently amended) The antibody of claim **10**, wherein the antibody is [[as]] obtainable by:

(a) immunising an animal with the peptide comprising the amino acid sequence VNQWSVNHD^xPVKW^yPN (SEQ ID NO: 1) or PExFD^xPARFLDKD^yGy, where x is D or N and y is L or F (SEQ ID NOs: 2 to 5), which peptide is conjugated to an immunogenic carrier;

(b) sacrificing the animal and fusing spleen cells obtained from the animal with myeloma cells to produce one or more hybridomas; and,

(c) screening the hybridomas for antibodies capable of binding the peptide.

Appl. No. 09/936,979
Response Dated July 26, 2007
Reply to Office Action of May 7, 2007

16. (Previously Presented) The antibody of claim 10, wherein the antibody is conjugated to an effector.

17. (Original) The antibody of claim 16, wherein the effector is a label, a toxin, a drug or prodrug, an enzyme or a transport molecule.

18. (Cancelled) The antibody of claim 10, for use in a method of medical treatment.

Claims 19 to 25 (Cancelled)